Result of Annual General Meeting

Oxford Biomedica PLC
24 June 2024
 

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 24 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that  all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 24 June 2024 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

 

Copies of the document setting out the above resolutions passed at the 2024 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

On the Record Date (20 June 2024) there were 105,268,630 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 

 

 

 

 

 

 

Resolution

 

Votes

For (incl. votes at the Chairman's discretion)

 

 

  

% of votes cast

 

Votes

Against

 

 


% of votes cast

 

Votes

Withheld*

 

Total

votes cast

Result

 

 

 

 

 

 

 

 

 

 

Ordinary resolutions
















 

 

 

 

1

 

To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2023, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports.

72,477,617

99.99%

4,552

0.01%

608,560

72,482,169

PASS

 

 

 

 

 

 

 

 

2

 

To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) for the financial year ended 31 December 2023.

72,347,034

99.61%

280,462

0.39%

463,233

72,627,496

PASS

 

 

 

 

 

 

 

3

 

To consider and, if thought fit, approve the Directors' Remuneration Policy, the full text of which is included in the Directors' Remuneration Report for the financial year ended 31 December 2023.

70,899,498

97.67%

1,691,080

2.33%

500,151

72,590,578

PASS

 

 

 

 

4

 

To appoint Peter Soelkner as a Director of the Company.

72,622,493

99.98%

11,817

0.02%

456,419

72,634,310

PASS

 

 

5

 

To reappoint Dr. Roch Doliveux as a Director of the Company.

72,614,517

99.97%

18,800

0.03%

457,412

72,633,317

PASS

 

 

6

To reappoint Stuart Henderson as a Director of the Company.

72,621,001

99.98%

13,309

0.02%

456,419

72,634,310

PASS

 

 

7

 

To reappoint Professor Dame Kay Davies as a Director of the Company.

72,619,922

99.98%

13,395

0.02%

457,412

72,633,317

PASS

 

 

8

 

To reappoint Dr. Frank Mathias as a Director of the Company.

72,623,288

99.99%

10,522

0.01%

456,919

72,633,810

PASS

 

 

9

 

To reappoint Stuart Paynter as a Director of the Company.

72,623,118

99.99%

10,199

0.01%

457,412

72,633,317

PASS

 

 

10

 

To reappoint Robert Ghenchev as a Director of the Company.

72,585,321

99.93%

47,996

0.07%

457,412

72,633,317

PASS

 

 

11

 

To reappoint Namrata Patel as a Director of the Company.

72,619,735

99.98%

13,582

0.02%

457,412

72,633,317

PASS

 

 

12

 

To reappoint Leone      Patterson as a Director of the Company.

71,427,129

98.34%

1,206,006

1.66%

457,594

72,633,135

PASS

 

 

13

 

To reappoint Dr. Heather Preston as a Director of the Company.

71,207,370

98.04%

1,425,964

1.96%

457,395

72,633,334

PASS

 

 

 

 

 

14

 

To appoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the meeting until the conclusion of the next AGM of the Company at which the accounts are laid.

72,579,009

99.98%

16,159

0.02%

495,561

72,595,168

PASS

 

 

 

 

 

 

15

 

To authorise the Audit Committee for and on behalf of the Board to determine the auditor's remuneration.

72,580,492

99.98%

15,389

0.02%

494,848

72,595,881

PASS

 

 

 

16

To approve the Oxford Biomedica 2024 Long Term Incentive Plan.

62,538,002

86.10%

10,095,007

13.90%

457,720

72,633,009

PASS

 

 

17

 

To approve the Oxford Biomedica 2024 Deferred Bonus Plan.

62,775,222

86.43%

9,856,415

13.57%

459,092

72,631,637

PASS

 

 

18

 

To approve the Oxford Biomedica 2024 Sharesave Scheme.

63,225,470

87.05%

9,408,593

12.95%

456,666

72,634,063

PASS

 

 

19

 

To authorise the Directors to allot shares.

72,168,633

99.41%

426,961

0.59%

495,135

72,595,594

PASS

 

 

20

 

To authorise the Directors to disapply pre-emption rights.

72,215,940

99.48%

378,341

0.52%

496,448

72,594,281

PASS

 

 

 

21

 

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.

72,215,440

99.48%

378,841

0.52%

496,448

72,594,281

PASS

 

 

 

 

22

 

To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

72,369,632

99.63%

265,377

0.37%

455,720

72,635,009

PASS

 

 

 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

 

 

 

 

 

 

 

 

In addition, further to the announcement by the Company on 11 March 2024, Dr. Michael Hayden and Catherine Moukheibir have stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.

 

-Ends-

 

For further information, please contact:


 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

ABOUT OXFORD BIOMEDICA

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100